Other weight-loss agents have faced setbacks, too. However, given the history of weight-loss drugs, particularly first-generation antiobesity agents such as dexfenfluramine and fenfluramine that increased the risk of pulmonary hypertension and valve problems, determining the long-term safety of lorcaserin was critical, according to investigators. In several trials to date-BLOSSOM, BLOOM, and BLOOM-Diabetes Mellitus-treatment with lorcaserin resulted in better sustained weight loss compared with placebo. Lorcaserin (Belviq, Eisai/Arena Pharmaceuticals), a selective agonist of 5-hydroxytryptamine 2C serotonin receptor (5-HT2C) that modulates appetite, was approved by the US Food and Drug Administration (FDA) in 2012 as an adjunct to a calorie-reduced diet and increased physical activity for weight management. Having a safe pharmacologic agent is useful and a “step forward” in the field, she said. Presenting the results during a press conference at the European Society of Cardiology Congress 2018, Bohula said lifestyle modification remains the cornerstone of weight-loss therapy for all patients, but adherence is challenging. This is the first time in a rigorous outcomes study we’ve been able to document cardiovascular safety, and for that reason I think it is a milestone and it’s important for patients and providers.” In the US, for example, obesity rates are around 40% so it is a major problem. And obesity is clearly a global problem-the rates overall have tripled in the last 40 years. “There have been a number approved for use and then found to have major safety signals and removed. “The history with weight-loss agents has been very challenging,” lead investigator Erin Bohula, MD, DPhil (Brigham and Women’s Hospital, Boston, MA). Importantly, in a subset of patients who underwent echocardiographic follow-up, CAMELLIA-TIMI 61 investigators did not observe any of the valve problems that have plagued anti-obesity agents in the past. MUNICH, Germany-A drug already approved in the United States for weight loss in overweight and obese patients does not increase the risk of cardiovascular events, according to the results of a large safety study.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |